Abstract
The review focuses on the issue of type 2 diabetes mellitus (T2D) in older patients and novel coronavirus infection (COVID-19). In accordance with the analyzed articles, comorbidity, pro-inflammatory state, diminished innate immune response, vascular dysfunction and tendency to thrombosis in people with T2D, contribute to a higher susceptibility to SARS-CoV-2 infection and a poor prognosis. The using of Subetta is possible in add-on therapy for older patients with transient hyperglycemia, insulin resistance and type 2 diabetes mellitus in order to achieve carbohydrate metabolic compensation and improve the quality of life.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
